Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion

Overview of attention for article published in OncoTargets and therapy, May 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 4 publications that cite this research output.

4

The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.

Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib

Article in Frontiers in Oncology (February 2024)

Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma

Article in Journal of Thoracic Disease (October 2022)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Article in Frontiers in Oncology (October 2021)